- The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION.
- NAION is a rare condition caused by decreased blood flow to the front part of the optic nerve and can result in sudden decreased vision, including permanent vision loss.
- NAION cases have been reported for all currently marketed GLP-1 products, the FDA said.
- = = =
NAION cases have been reported for all currently marketed GLP-1 products, the FDA said.
Ozempic and Wegovy maker Novo Nordisk said it “continues to believe the data do not establish a cause-and-effect relationship, and we remain confident in the benefit-risk profile of our GLP-1 medicines.”
Eli Lilly, the company behind Mounjaro, Zepbound and Foundayo, said it is “carefully evaluating the update and will respond to FDA promptly.” Patient safety is Lilly’s “top priority,” the drugmaker added.
Diabetes itself is a known risk factor for NAION, complicating efforts to determine if cases among GLP-1 users are caused by the medications or by patients’ underlying health conditions.
The FDA decision follows a review of clinical trials, real-world patient data, and published studies.
An analysis of 126 trials involving more than 134,000 patients found 6.4 cases of NAION per 100,000 patient-years among GLP-1 users, compared with 3.8 among patients receiving other treatments or placebos.
The FDA said it identified 15 probable NAION events, 10 in patients treated with GLP-1s and five in patients receiving a placebo, and no cases were identified among patients receiving other non-GLP-1 glucose-lowering medications.
This blog is fanatic about FunFood (i.e. FUNctional Food to make us happier and healthier).
Tuesday, 17 November 2026
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment